We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

I think the GSK share price could help you retire early

The GSK share price looks to have the potential to produce large total returns for long-term investors in the years ahead.

You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.

Of all the 100 different stocks in the FTSE 100, I think the GSK (LSE: GSK) share price has more potential to help you retire early than most. 

It all comes down to the company’s defensive nature. 

Should you buy Rolls Royce shares today?

Before you decide, please take a moment to review this report first. Despite ongoing uncertainties from US tariffs to global conflicts, Mark Rogers and his team believe many UK shares still trade at substantial discounts, offering savvy investors plenty of potential opportunities to learn about.

That’s why this could be an ideal time to secure this valuable research – Mark’s analysts have scoured the markets to reveal 5 of his favourite long-term ‘Buys’. Please, don’t make any big decisions before seeing them.

GSK share price growth 

Healthcare is one of the world’s most defensive markets. The treatments and products produced by GSK will always be required, and as the population grows, so will demand. 

But there’s more to GSK that its existing portfolio of drugs and medications. The company also spends billions of pounds every year researching new treatments. These products are designed to combat existing diseases and viruses, as well as new threats. The group is always trying to think of new ways to treat old problems and to address new issues. 

Management also considers acquisitions regularly. These efforts should help the company maintain its edge in the global pharmaceutical industry, not just in the short term, but in the long run as well.

This is the primary reason why the GSK share price could make an excellent buy-and-forget investment. Its products will always be in demand, and demand will only grow over the long run. That means to a certain extent the business runs itself. 

The company’s consumer pharmaceuticals division is another positive factor. Management is planning to spin off this business in the near term, which could create a windfall for shareholders. A special dividend or shares in the business may be distributed to existing GSK share price holders. 

Income returns 

It’s also good news for income seekers. GSK’s defensive business model means that the company has a relatively stable and predictable income stream from operations. This supports an attractive dividend yield on the GSK share price. 

Indeed, over the past few months, many FTSE 100 businesses have been forced to cut or eliminate their dividends to conserve cash in the coronavirus crisis. GSK is one of the few companies in the index that has not taken this course of action.

As a result, at the time of writing the stock supports a dividend yield of 4.9%, above the FTSE 100 average of around 4%. This looks set to continue as the dividend is well covered by earnings per share. The dividend cover stands at 1.5.

Retire early 

All of the above suggests that the GSK share price may be an excellent buy for any investor’s retirement portfolio. 

Over the long term, earnings per share should grow at least in line with inflation. That implies the company can achieve long-run earnings growth of 3% or more. Coupled with its 4.9% dividend yield, these numbers infer that the stock can produce total returns of 7.9% in the long term. 

This rate of return is more than enough to help you grow your financial nest egg. According to my calculations, an investment of £200 a month growing at a rate of 7.9% per annum could grow to be worth as much as £300,000 after 30 years. 

Rupert Hargreaves owns no share mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Tree lined "tunnel" in the English countryside of West Sussex in autumn
Investing Articles

3 UK shares to consider holding in a Stocks and Shares ISA for a decade

Mark Hartley explains why he thinks these three stocks would make great additions to a long-term Stocks and Shares ISA…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

Where should value investors look for stocks in June?

Value investors looking for stocks to buy might be uneasy with artificial intelligence. But other industries look much more attractive…

Read more »

Investing Articles

The latest broker outlooks on Greggs shares look wacky, so what’s happening?

Analyst price targets for Greggs shares are creating some mixed sentiments on where the high-street baker might go next in…

Read more »

Caerphilly Castle, and reflection in the moat.
Investing Articles

2 FTSE 100 dividend stocks that stand out for shareholder returns

Andrew Mackie highlights two FTSE 100 dividend stocks where disciplined capital allocation could continue driving shareholder returns.

Read more »

Senior Adult Black Female Tourist Admiring London
Investing Articles

Just 9% of us can expect a ‘comfortable’ retirement! Could UK shares be the answer?

Millions of Brits could miss out on the retirement of their dreams. Might they avoid this by investing in UK…

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

3 passive income shares to consider buying for a 7% yield

Harvey Jones picks out three UK income shares that offer terrific dividends and are trading at tempting valuations. None of…

Read more »

Businessman hand stacking up arrow on wooden block cubes
Investing Articles

How much just £4,160 invested in Rolls-Royce shares 5 years ago is worth now

Rolls-Royce shares have been on a remarkable run of late. Ken Hall takes a look at the key drivers and…

Read more »

Cropped shot of an affectionate young couple posing with a bunch of flowers in their kitchen on their anniversary
Investing Articles

The FTSE 100’s Howden Joinery just made a bold move — should investors care?

Andrew Mackie looks at the FTSE 100’s Howden Joinery and its move into online kitchens, asking what the acquisition means…

Read more »